Avatrombopag (Doptelet)

From HemOnc.org - A Hematology Oncology Wiki
Revision as of 12:40, 7 July 2014 by Jwarner (talk | contribs) (Created page with "==Mechanism of action== Thrombopoietin receptor agonist ==Preliminary data== <span style="background:#00CD00; padding:3px 6px 3px 6px; border-color:black; border-width:2px; ...")
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search

Mechanism of action

Thrombopoietin receptor agonist

Preliminary data

Randomized Phase II, >20 per arm

  1. Bussel JB, Kuter DJ, Aledort LM, Kessler CM, Cuker A, Pendergrass KB, Tang S, McIntosh J. A randomized trial of avatrombopag, an investigational thrombopoietin-receptor agonist, in persistent and chronic immune thrombocytopenia. Blood. 2014 Jun 19;123(25):3887-94. Epub 2014 May 6. link to original article PubMed

Also known as

YM477, AKR 501

Retrieved from "https://hemonc.org/w/index.php?title=Avatrombopag_(Doptelet)&oldid=4894"